ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

セスロマイシン

(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-11-{[3-(quinolin-3-yl)prop-2-en-1-yl]oxy}tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside

HCID 447451
ノート反応
基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
205110-48-1
標準SMILES
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC/C=C/c2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C
InChIKey
PENDGIOBPJLVBT-ONLVEXIXSA-N
分子式
C42H59N3O10
平均分子量
765.9 g/mol
単同位体質量
765.42004509

概要

Cethromycin is a macrolide antibiotic which displays in vitro activity against both gram-positive and gram-negative bacteria and is currently under investigation for the treatment of community-acquired pneumonia. The US Food and Drug Administration (FDA) have also granted orphan drug designation to cethromycin for the treatment of anthrax prophylaxis, tularemia, and plague (PDB entry: 1NWX). It has a role as an antibacterial drug and a protein synthesis inhibitor. It is a macrolide antibiotic, a member of quinolines and a monosaccharide derivative.

名称と識別子

優先名称
(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-11-{[3-(quinolin-3-yl)prop-2-en-1-yl]oxy}tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside
IUPAC
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
現地名
セスロマイシン
英語名
CETHROMYCIN
分子式
C42H59N3O10
分子量
765.93

名称と別名

Cethromycin [USAN]Cethromycin (USAN/INN)CETHROMYCIN [MI]CETHROMYCIN [INN]CETHROMYCIN [MART.]CETHROMYCIN [WHO-DD]A-195773.0ABT773SCHEMBL1818083GTPL10791(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-11-{[3-(quinolin-3-yl)prop-2-en-1-yl]oxy}tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosideBDBM50511979
名称をさらに表示
セスロマイシンABT-7735-O-[3,4,6-トリデオキシ-3-(ジメチルアミノ)-β-D-xylo-ヘキソピラノシル]-6-O-[3-(キノリン-3-イル)-2-プロペニル]-3,11,12-トリデオキシ-3,23-ジオキソ-12,11-(エポキシメタノイミノ)エリスロノリドAセトロマイシン3,11,12-トリデオキシ-3,23-ジオキソ-6-O-[3-(キノリン-3-イル)-2-プロペニル]-5-O-[3-(ジメチルアミノ)-3,4,6-トリデオキシ-β-D-xylo-ヘキソピラノシル]-12,11-(エポキシメタノイミノ)エリスロノリドA11,12-(イミノカルボニルオキシ)-11,12-ジデオキシ-3-オキソ-3-デス(2,6-ジデオキシ-3-C-メチル-3-O-メチル-α-L-ribo-ヘキソピラノシルオキシ)-6-O-[3-(3-キノリル)アリル]エリスロマイシン

物性

構造計算による物性

XLogP
5.4
極性表面積
163 Ų
水素結合供与体数
2
水素結合受容体数
12
回転可能結合数
8
重原子数
55
形式電荷
0
複雑度
1,410

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15

物理化学的性質

融点
211 · 211-213°
沸点
927.1 · 927.1±65.0 °C(Predicted)
比重(密度)
1.22 · 1.22±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · Store at -20°C
外見
Solid
酸解離定数(Pka)
10.84 · 10.84±0.70(Predicted)
色
White to off-white

化学と産業

薬理情報

Protein BindingCethromycin displays 86.7 to 95.6% human plasma protein binding over a range of concentrations between 0.1 to 30.0 μg/ml.
Pharmacodynamics · 1 件

Cethromycin binds to the 50S subunit of the bacterial ribosome to inhibit both ribosome assembly and bacterial protein synthesis. Adverse effects such as diarrhea, nausea, vomiting, and headache may be due to off-target inhibition of molecules within mammalian cells.

Mechanism of Action · 1 件

Respiratory tract infections can be caused by numerous strains of bacteria, requiring careful consideration of treatment and antibiotics effective against a broad spectrum of potential pathogens. Cethromycin, like other macrolide antibiotics, binds to the 23S rRNA of the 50S subunit of the bacterial ribosome. This binding, primarily mediated through regions II and V of the rRNA, occludes the peptide exit tunnel and inhibits bacterial protein synthesis. In addition, cethromycin is capable of binding to ribosomal intermediates during ribosome biogenesis, inhibiting the formation of functional 70S bacterial ribosomes. Due to the sequence and structural similarity of ribosomes between species, cethromycin displays broad-spectrum activity against diverse Gram-positive, Gram-negative, and atypical bacteria.

Biological Half-LifeCethromycin given in five oral doses of 150 or 300 mg has a plasma half-life of 4.85 ± 1.10 and 4.94 ± 0.66 hrs, respectively. A single oral dose of 150 mg produced a measured half-life of 5.66 ± 0.77 hrs.
Metabolism/Metabolites · 1 件

Extensive studies of cethromycin metabolism have not been conducted, although one study identified seven metabolites within feces of patients administered a single 150 mg oral dose. The major recovered products were unchanged cethromycin and an inactive N-desmethyl metabolite. It is likely that most of the metabolism occurs in the liver and is mediated, at least in part, by CYP3A4.

Absorption, Distribution and Excretion · 4 件

Cethromycin displays non-linear absorption kinetics. In healthy adults administered 150 mg cethromycin orally once daily for five doses, the calculated Cmax, Tmax, and AUC0-24 values were 0.181 ± 0.084 μg/ml, 2.01 ± 1.30 hrs, and 0.902 ± 0.469 μg\*h/ml, respectively. Similarly, the corresponding values for a 300 mg dose were 0.500 ± 0.168 μg/ml, 2.09 ± 0.03 hrs, and 3.067 ± 1.205 μg\*h/ml, respectively. In another study using a single oral dose of 150 mg cethromycin, the Cmax was 318 ± 161 ng/ml, the Tmax was 1.79 ± 0.50, the AUC0-24 was 1596 ± 876 ng\*h/ml, and the AUC0-∞ was 1662 ± 907 ng\*h/ml.

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(ジメチルアミノ)-3-ヒドロキシ-6-メチルオキサン-2-イル]オキシ}-4-エチル-3a,7,9,11,13,15-ヘキサメチル-11-{[3-(キノリン-3-イル)プロパ-2-エン-1-イル]オキシ}-テトラデカヒドロ-1H-オキサシクロテトラデカ[4,3-d][1,3]オキサゾール-2,6,8,14-テトラオン
ABT-773
Restanza
A-195773
CETHROMYCIN
Abbott-195773
quinerythromycin
CETHROMYCIN(ABT-773)
11-Amino-11-deoxy-3-oxo-5-o-desosaminyl-6-o-[1'-(3'-quinolyl-2'-propenyl)] erythronolide A 11,12-cyclic carbamate
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-
DB06419DA-72101NS00070486D02391(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-11-{[(2E)-3-quinolin-3-ylprop-2-en-1-yl]oxy}tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside

データベース識別子

CAS
205110-48-1
PubChem CID
447451
ChEBI
CHEBI:29506
UNII
J0086219X6

Cethromycin is primarily excreted by the biliary route, with 87.2% of an initial dose recovered in feces and only 7.0% in urine. Unchanged cethromycin accounted for 35.7% of the radioactivity recovered in feces and an N-desmethyl metabolite for 39.8%; the remaining radioactivity was approximately evenly divided between three minor metabolites and a group of uncharacterized additional products.

Cethromycin given in five 150 mg oral doses had an apparent volume of distribution at the terminal elimination phase of 1433 ± 843 L, and an apparent steady-state volume of distribution of 1453 ± 997 L. The corresponding values for a 300 mg dose was 761 ± 293 L and 769 ± 272 L. Cethromycin is known to accumulate in the epithelial lining fluid and alveolar cells, as well as within polymorphonuclear leukocytes.

Cethromycin clearance in patients receiving a once-daily oral dose of 300 mg is reported to be approximately 63 L/h.

応用分野 · 2 件

説明Cethromycin (formerly ABT-773) is a ketolide antibiotic originally developed by Abbott in the late 1990s, but abandoned in 2002. Since 2004, Advanced Life Sciences has promoted current development of cethromycin. The ketolides are structurally derived from erythromycin A and are designed to overcome resistance to macrolides. One of the main features is the lack of the neutral sugar L-cladinose at position 3 of the erythonolide ring, which is replaced by a keto group (thus giving rise to the class name). Lack of the L-cladinose moiety results in better drug absorption and less gastric irritation through improved acid stability.

使用Antibacterial.

サプライヤー14 社

Shaanxi Cuikang Pharmaceutical Technology Co., Ltd+86-13119157289 · [email protected]
南京世洲生物科技有限公司025-025-85560043 17301488900 · [email protected]
上海赛可锐生物科技有限公司021-58000709 13120558703 · [email protected]
玺标(上海)科技有限公司18512111473 18512111473 · [email protected]
上海喀露蓝科技有限公司18149758185 18149758185 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
上海波以尔化工有限公司021-50182298 021-50180596 · [email protected]
浙江珲达生物科技有限公司0571-89903022 18679456698 · [email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
范德(北京)生物科技有限责任公司15911056312 · [email protected]
SHANGHAI KEAN TECHNOLOGY CO., LTD.+8613817748580 · [email protected]
BOC Sciences+1-631-485-4226 · [email protected]
南京世洲生物科技有限公司18351873721 · [email protected]
InvivoChem+1-708-310-1919 +1-13798911105 · [email protected]